Coagulation defects, purpura and other haemorrhagic conditions

D3_COAGDEF_PURPUR_HAEMORRHAGIC

No definition available.

Endpoint definition

FinnGen phenotype data

392423 individuals

diagram downward connector

Apply sex-specific rule None

392423

diagram downward connector

Check conditions None

392423

diagram downward connector

Check pre-conditions, main-only, mode, registry filters None

0 out of 7 registries used, show all original rules.

0

diagram downward connector

Check minimum number of events None

0

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

5773

diagram downward connector
D3_COAGDEF_PURPUR_HAEMORRHAGIC

Control definitions

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy 2
First used in FinnGen datafreeze DF2

Similar endpoints

List of similar endpoints to Coagulation defects, purpura and other haemorrhagic conditions based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Broader endpoints:

Venn diagram with a set fully inside an highlighted set Narrower endpoints:

Show all endpoint correlations

Summary Statistics

Key figures

All Female Male
Number of individuals 5773 3283 2490
Unadjusted prevalence (%) 1.53 1.56 1.50
Mean age at first event (years) 49.95 45.25 56.15

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.10 6.82 [4.91, 9.48] 3.0e-30 997
15 years 0.01 1.96 [1.50, 2.56] 6.8e-7 221
5 years 0.01 5.43 [4.05, 7.27] 6.1e-30 271
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: D3_COAGDEF_PURPUR_HAEMORRHAGIC – Coagulation defects, purpura and other haemorrhagic conditions
GWS hits: 5

Survival analyses between endpoints

Plot

before Coagulation defects, purpura and other haemorrhagic conditions
after Coagulation defects, purpura and other haemorrhagic conditions

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Coagulation defects, purpura and other haemorrhagic conditions

Endpoint not on priority list, no data to show.